Pricing Log in Create free account
Saturday 17 October 2026 Export REPL’s income statement to Excel — free account

Replimune Group, Inc.

REPL Healthcare Biotechnology

In the quarter to June 2026, EPS grew 24.2%, free cash flow grew 5.04% and total debt rose 52.6%, each against the same quarter a year earlier.

10.86 0.89 −7.57%
Market cap
$1.1B
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Replimune Group, Inc. (REPL) Business Profile

Updated before January 2025

Company Overview

Replimune Group, Inc. (NASDAQ: REPL) is a biotechnology company specializing in the development of oncolytic immunotherapies to treat cancer. Founded in 2015 by Dr. Robert Coffin, who is also the inventor of T-VEC, the first FDA-approved oncolytic immunotherapy, Replimune is headquartered in Woburn, Massachusetts, USA. The company’s mission is to revolutionize cancer treatment by leveraging its proprietary Immulytic™ platform to develop therapies that combine direct tumor destruction with immune system activation.

Replimune’s leadership team includes experienced professionals in the biotechnology and pharmaceutical industries. Dr. Robert Coffin serves as the President and CEO, bringing decades of expertise in virology and immunotherapy. Other key executives include Dr. Colin Love, Chief Operating Officer, and Jean Franchi, Chief Financial Officer, who collectively contribute to the company’s strategic direction and operational excellence.

Core Business Segments

Replimune focuses on the development of oncolytic immunotherapies, which are viruses engineered to selectively infect and kill cancer cells while stimulating an anti-tumor immune response. The company’s core business segments include:

1. Immulytic™ Platform

The Immulytic™ platform is the foundation of Replimune’s product pipeline. It is designed to enhance the efficacy of oncolytic viruses by incorporating additional therapeutic genes and optimizing virus delivery. Key products under this platform include:

  • RP1 (vusolimogene oderparepvec): A lead product candidate designed to treat a variety of solid tumors, including melanoma, non-melanoma skin cancers, and head and neck cancers. RP1 is currently in Phase 2 and Phase 3 clinical trials.
  • RP2: An enhanced version of RP1 that includes an additional gene to further stimulate the immune system. RP2 is being evaluated in combination with immune checkpoint inhibitors.
  • RP3: A next-generation oncolytic immunotherapy designed to target tumors that are less responsive to immune checkpoint blockade therapies. RP3 is in early-stage clinical trials.

2. Combination Therapies

Replimune is actively exploring the use of its oncolytic immunotherapies in combination with other cancer treatments, such as immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1 therapies). These combination approaches aim to improve patient outcomes by leveraging synergistic mechanisms of action.

3. Manufacturing and Supply Chain

Replimune operates its own state-of-the-art manufacturing facility in Framingham, Massachusetts. This facility ensures the company’s ability to produce high-quality oncolytic immunotherapies at scale, supporting clinical trials and future commercialization efforts.

Business Model

Replimune’s business model is centered around the research, development, and commercialization of innovative cancer therapies. The company generates revenue primarily through partnerships, licensing agreements, and, in the future, product sales. Key aspects of its business model include:

  • Research and Development (R&D): Replimune invests heavily in R&D to advance its pipeline of oncolytic immunotherapies. The company collaborates with academic institutions and industry partners to accelerate innovation.
  • Clinical Trials: Replimune conducts rigorous clinical trials to demonstrate the safety and efficacy of its therapies. Positive trial results are critical for regulatory approval and market adoption.
  • Strategic Partnerships: The company collaborates with pharmaceutical companies, such as Bristol Myers Squibb, to explore combination therapies and expand its market reach.
  • Manufacturing Excellence: By maintaining in-house manufacturing capabilities, Replimune ensures quality control and cost efficiency.

Strategic Direction

Replimune’s strategic direction focuses on expanding its pipeline, advancing clinical trials, and preparing for commercial launch. Key priorities include:

  • Pipeline Expansion: Replimune aims to develop additional oncolytic immunotherapies targeting a broader range of cancers. The company is also exploring the use of its therapies in earlier lines of treatment.
  • Global Market Penetration: Replimune plans to expand its presence in international markets by pursuing regulatory approvals in Europe, Asia, and other regions.
  • Sustainability Goals: The company is committed to sustainable practices in its operations, including energy-efficient manufacturing and minimizing environmental impact.
  • New Product Categories: Replimune is exploring the potential of its Immulytic™ platform in non-cancer indications, such as infectious diseases and autoimmune disorders.

Competitive Landscape

Replimune operates in a competitive biotechnology sector, facing competition from companies developing oncolytic viruses and other immunotherapies. Key competitors include:

  • Amgen: A leader in oncolytic immunotherapy with its FDA-approved T-VEC (Imlygic®).
  • Oncorus: A biotechnology company focused on next-generation oncolytic viruses.
  • Turnstone Biologics: Specializes in oncolytic virus therapies and cancer vaccines.
  • BioVex: Another player in the oncolytic virus space, with a focus on personalized cancer treatments.

Replimune differentiates itself through its proprietary Immulytic™ platform, robust clinical pipeline, and strategic partnerships.

Risk Factors

Replimune faces several risks that could impact its business operations and financial performance:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals could hinder product commercialization.
  • Market Dependence: The company’s success depends on the adoption of its therapies by healthcare providers and patients.
  • Clinical Trial Risks: Unfavorable trial results could delay or prevent product development.
  • Supply Chain Disruptions: Dependence on raw materials and manufacturing processes poses risks of supply chain interruptions.
  • Competition: Intense competition in the biotechnology sector could limit market share and pricing power.

Recent Developments

Replimune has made significant progress in advancing its clinical pipeline and corporate strategy. Recent developments include:

  • Clinical Trial Updates: Positive interim results from Phase 2 and Phase 3 trials of RP1 in combination with immune checkpoint inhibitors.
  • Partnerships: Expanded collaboration with Bristol Myers Squibb to evaluate combination therapies.
  • Manufacturing Milestones: Completion of the Framingham manufacturing facility, enabling large-scale production of oncolytic immunotherapies.
  • Global Developments: Increased focus on regulatory submissions in Europe and Asia to expand market access.

Investment Considerations

Investors considering Replimune should weigh the following strengths and risks:

Strengths

  • Innovative Immulytic™ platform with broad therapeutic potential.
  • Robust clinical pipeline targeting multiple cancer types.
  • Strategic partnerships with leading pharmaceutical companies.
  • In-house manufacturing capabilities ensuring quality and scalability.

Risks

  • Dependence on clinical trial success and regulatory approvals.
  • High R&D expenses and potential delays in product commercialization.
  • Competitive pressures from established and emerging players.
  • Market adoption challenges for novel therapies.

Conclusion

Replimune Group, Inc. is at the forefront of oncolytic immunotherapy, leveraging its proprietary Immulytic™ platform to develop innovative cancer treatments. With a strong clinical pipeline, strategic partnerships, and in-house manufacturing capabilities, the company is well-positioned for future growth. However, investors should carefully consider the risks associated with clinical development and market adoption. As Replimune advances its therapies and expands its global footprint, it has the potential to make a significant impact on cancer treatment and deliver long-term value to stakeholders.